vol.25 July 2022

KOBE Biomedical Innovation Cluster newsletter vol.25
- July 2022 -

vol.25 July 2022

Hello,

Last month, June, was a month of many shareholder meetings. This has a lot to do with the fact that more than half of companies with over $1 million capital begins their fiscal year in April, which we mentioned in the opening message of the newsletter in April. This is especially true for June 29, which is the date that 26% of listed companies that hold their ordinary shareholders’ meeting in June took place on. In the past, there is a year that 96% of companies held it on this date. The early web disclosure of meeting notices and the electronic voting have expanded the opportunities for shareholders to exercise their rights. The number of companies holding virtual shareholders’ meetings, especially under COVID-19, has increased, providing shareholders with greater opportunities to attend and participate from distant locations. While an increasing number of companies are providing English-language convocation notices, there are still some issues to be addressed, such as the fact that general meetings are mostly held only in Japanese but seems that the environment is gradually becoming to facilitate the participation by people from overseas.

Why did we take up the topic of June in July? Recently, an increasing number of companies are holding or considering holding their general shareholders' meetings in July to avoid the concentrated holding dates.　

If you missed our recent topics, please visit Newsletter Archive page.

FBRI Editorial Team

NEWS

FBRI’s research on Acute Myeloid Leukemia publish in “Blood” ~ Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia ~

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
Summary:
・A novel EVI1 splice isoform is frequently expressed in poor-prognostic leukemia harboring inv(3)/t(3;3) and drives myeloid transformation.
・Frequent SF3B1 mutations in inv(3)/t(3;3) leukemia generate a novel EVI1 isoform with an altered second Zinc finger DNA-binding domain.
・These results explain the reason why splicing factor SF3B1 mutation is very frequently mutated in inv(3)/t(3;3) leukemia

Sysmex Announced the Completion of Declaration of Conformity to the European IVD Directive for an Assay Kit that Measures Plasma Amyloid Beta (Aβ) Using the Automated Immunoassay System HISCLTM-5000/HISCLTM-800
(Published: June 27, 2022)

Sysmex Corporation announces that it has completed a declaration of conformity to the European IVD Directive for an assay kit to measure Aβin the blood using its automated immunoassay system HISCL-5000/HISCL-800 (“the assay kit”).

HEALIOS K.K. Exercises Exclusive Option for a License Agreement with STEMAXON for the Development of UDC-Derived Photoreceptor Cells
(Published: July 12, 2022)

HEALIOS K.K. announces that it has exercised option rights and entered into exclusive negotiations with STEMAXON (Head office: Montreal, Canada; CEO: Gilbert Bernier, PhD; hereinafter referred to as "StemAxon"), a Canadian bio-venture company, in relation to a license agreement for technology to differentiate stem cells, including iPS cells, into photoreceptor cells.

Are you ready to expand your business in Japan?
Here's a complete guide that tells everything you need to
know about starting up your business in Japan!

1. Business Startup Overview
2. All you need to know about the Startup VISA
3. Renting a House and Resident Registration
4. Obtaining a Phone Number, a Name Seal and Personal Bank Account
5. Business Manager VISA
6. Incorporating a Business and Renting an Office
7. How to open corporate bank account
8. How to Sign Up for Social and Labor Insurance
9. Introducing Kobe Biomedical Innovation
10. Testimonials

Download Report

Grow Your Medical Business in Kobe!

We help international medical business thrive in Japan with world-class research institutes and facilities.

The Japanese MedTech & HealthTech Market 2021

Learn extensive insights into the Japanese MedTech market trend including a breakdown of major diseases and medical expenditures, healthcare systems as well as regulations and key players in the MedTech market in Japan.